DUS2

Across TCGA pan-cancer cohorts, DUS2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of DUS2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where DUS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DUS2 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BLCA, HNSC, and KIRP are the cancer types where DUS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DUS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	+0.960	<.001	11	view →
HNSC	Female	IV	+0.953	<.001	11	view →
KIRP	All	IV	+0.827	<.001	11	view →
KIRC	Female	All	+0.405	<.001	11	view →
THCA	Male	III,IV	−0.652	<.001	10	view →
LIHC	Male	II,III,IV	+0.812	<.001	9	view →
STAD	Male	II,III,IV	+0.804	<.001	8	view →
LUSC	All	II,III,IV	+0.539	<.001	8	view →
COAD	Female	All	+0.439	<.001	8	view →
LUAD	All	All	+0.280	<.001	7	view →
CHOL	Male	All	+1.418	<.001	5	view →
UCEC	All	III,IV	+0.516	.048	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

DUS2–BLCA

Open the BLCA breakdown →